Список литературы

1. Travis SP, Dinesen L. Remission in trials of ulcerative colitis: what does it mean? Pract Gastroenterol 2010; 30: 17 - 20.

2. D"Haens G, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763 - 86

3. Benchimol E.I., Fortinsky K.J., Gozdyra P. et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm. Bowel. Dis. 2011; 17: 423 - 439.

4. Henderson P., Hansen R., Cameron F.L. et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm. Bowel. Dis. 2012; 18: 999 - 1005.

5. Heyman M.B., Kirschner B.S., Gold B.D. et al. Children with earlyonset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J. Pediatr. 2005; 146: 35 - 40.

6. Van Limbergen J., Russell R.K., Drummond H.E. et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008; 135: 1114 - 1122.

7. 5. Gower-Rousseau C, Dauchet L., Vernier-Massouille G. et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am. J. Gastroenterol. 2009; 104: 2080 - 2088.

8. Travis S. P. L., Stange E.F., Lerfnann M. et al. European evidencebased consensus on the management of ulcerative colitis: current management. J. Crohn Colitis. 2008; 2: 24 - 62.

9. Turner D., Travis S.P., Griffiths A.M. et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBDWorking Group of ESPGHAN. Am. J. Gastroenterol. 2011; 106: 574 - 588.

10. Turner D, Levine A, Escher JC et al. Management of Pediatric Ulcerative Colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines. J. Pediatr. Gastroenterol. Nutr. 2012; 55: 340 - 361.

11. Rodeman JF, Dubberke ER, Reske KA et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 339 - 344

12. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1432 - 42

13. Nguyen GC, Kaplan GG, Harris ML et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103: 1443 - 50

14. Mindenmark M, Larsson A. Rulling out IBD estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. CHnBiochem 2012; 45: 552 - 5

15. Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642 - 7.

16. Mack D.R., Langton C., Markowitz J. et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007; 119: 1113 - 1119.

17. Weinstein T.A., Levine M., Pettei M.J. et al. Age and family history at presentation of pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2003; 37: 609 - 613.

18. Henderson P., Casey A., Lawrence S.J. et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am. J. Gastroenterol. 2012; 107: 941 - 949.

19. Venediktova M.M., Tsimbalova E.G., Potapov A.S., Mayanskii N.A. Voprosi diagnostiki v pediatrii - Diagnostics in pediatrics. 2011; 3 (6): 23 - 26.

20. Turner D., Leach S.T., Mack D. et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010; 59: 1207 - 1212.

21. Sylvester F.A., Turner D., Draghi A., 2nd et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflamm. Bowel. Dis. 2011; 17: 1726 - 1730.

22. Beattie R.M., Nicholls S.W., Domizio P. et al. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 1996; 22: 373 - 379.

23. Glickman J.N., Bousvaros A., Farraye F.A. et al. Pediatric patients with untreated ulcerative colitis may present initially with unusual morphologic findings. Am. J. Surg. Pathol. 2004; 28: 190 - 197.

24. Levine A., de Bie C.L., Turner D. et al. Atypical disease phenotypes in paediatric ulcerative colitis: 5-year analyses of the EUROKIDS registry. Inflamm. Bowel Dis. 2013 Feb; 19 (2): 370 - 7.

25. Robert M.E., Tang L., Hao L.M. et al. Patterns of inflammation in mucosal biopsies of ulcerative colitis: perceived differences in pediatric populations are limited to children younger than 10 years. Am. J. Surg. Pathol. 2004; 28: 183 - 189.

26. Haskell H., Andrews C.W., Jr., Reddy S.I. et al. Pathologic features and clinical significance of "backwash" ileitis in ulcerative colitis. Am. J. Surg. Pathol. 2005; 29: 1472 - 1481.

27. de Bie C.I., Buderus S., Sandhu B.K. et al. Diagnostic workup of paediatric patients with inflammatory bowel disease in Europe: results of a 5-year audit of the EUROKIDS registry. J. Pediatr. Gastroenterol. Nutr. 2012; 54: 374 - 380.

28. Корнеева О.И., Ивашкин В.Т. Антибиотикоассоциированный колит: патоморфология, клиника, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007. Т. 17. N 3. С. 65 - 71

29. Ивашкин В.Т., Шептулин А.А., Шифрин О.С, Галимова С.Ф., Юрманова Е.Н. Микроскопический колит: клинические формы, диагностика, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006. Т. 16, N 6. С. 56 - 60

30. Koletzko S., Niggemann B., Arato A. et al. Diagnostic approach and management of cow's milk protein allergy in infants and children: a practical guideline of the GI-committee of ESPGHAN. J Pediatr Gastroenterol Nutr. 2012; 55: 221 - 229.

31. Glocker E.O., Frede N., Perro M. et al. Infant colitis - it's in the genes. Lancet. 2010; 376: 1272.

32. Glocker E.O., Kotlarz D., Boztug K. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 2009; 361: 2033 - 2045.

33. Begue B., Verdier J., Rieux-Laucat F. et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am. J. Gastroenterol. 2011; 106: 1544 - 1555.

34. Белоусова Е.А., Никитина Н.В., Цодикова О.М. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. 2013. N 2. С. 42 - 46

35. Халиф И.Л. Лечебная тактика при язвенном колите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2006. Т 16. N 3. С. 58 - 62

36. Dignass A, et al, Second EUROPEAN evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management, Journal of Crohn"s and Colitis (2012).

37. Ford A.C, Khan K.J., Sandborn W.J. et al. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin. Gastroenterol. Hepatol. 2012; 10: 513 - 519.

38. Kolho K.L., Raivio T., Lindahl H. et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand. J. Gastroenterol. 2006; 41: 720 - 725.

39. Powell-Tuck J., Bown R.L., Lennard-Jones J.E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand. J. Gastroenterol. 1978; 13: 833 - 837.

40. Uchida K., Araki T., Toiyama Y. et al. Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis. Dis. Colon Rectum. 2006; 49: 74 - 79.

41. Timmer A., McDonald J. W., Macdonald J. K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochr. Database Syst. Rev. 2007: CD000478.

42. Gisbert J.P., Linares P.M., McNicholl A.G. et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment. Pharmacol. Ther. 2009; 30: 126 - 137.

43. Khan K.J., Dubinsky M.C., Ford A.C. et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 2011; 106: 630 - 642.

44. Barabino A., Torrente F., Ventura A. et al. Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment. Pharmacol. Ther. 2002; 16: 1125 - 1130.

45. Kader H.A., Mascarenhas M.R., Piccoli D.A. et al. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 1999; 28: 54 - 58.

46. Verhave M., Winter H.S., Grand R.J. Azathioprine in the treatment of children with inflammatory bowel disease. J. Pediatr. 1990; 117: 809 - 814.

47. Pozler O., Chladek J., Maly J. et al. Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. J. Crohns Colitis. 2010; 4: 623 - 628.

48. Sandborn W.J. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am. J. Gastroenterol. 1996; 91: 423 - 433.

49. De Greef E., Vandenplas Y., Veereman-Wauters G. Opportunistic infections in paediatric inflammatory bowel disease patients. Arch. Dis. Child. 2011; 91: 5 - 7.

50. Russell R.K., Wilson M.L., Loganathan S. et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2011; 33: 946 - 953.

51. Turner D., Griffiths A.M. Acute severe ulcerative colitis in children: a systematic review. Inflamm. Bowel. Dis. 2011; 17: 40 - 449.

52. Lawson M.M., Thomas A.G., Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochr. Database Syst. Rev. 2006: CD005112.

53. Rutgeerts P., Sandborn W.J., Feagan B.G. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl.J. Med. 2005; 353: 2462 - 2476.

54. Hyams J., Damaraju L., Blank M. et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 2012; 10: 391 - 399.

55. Baranov A.A., Potapov A.S., Tsimbalova E.G. Vestnik Rossiiskoi akademii meditsinskikh nauk - Annals of the Russian Academy of Medical Sciences. 2011; 6: 36 - 41.

56. Hyams J.S., Lerer T., Griffiths A. et al. Outcome following infliximab therapy in children with ulcerative colitis. Am. J.Gastroenterol. 2010; 105: 1430 - 1436.

57. Panaccione R., Ghosh S., Middleton S. et al. Infliximab, azathioprine or infliximab-azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J. Crohns Colitis. 2011; 5: 13.

58. Lichtenstein G.R., Diamond R.H., Wagner C.L. et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment. Pharmacol. Ther. 2009; 30: 210 - 226.

59. Chaparro M., Guerra I., Munoz-Linares P. et al. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2012; 35: 971 - 986.

60. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010; 16: 112 - 24.

61. Markel TA, Lou DC, Pfefferkorn M, et al. Steroids and poor nutrition are associated with infectious wound complications in children undergoing first stage procedures for ulcerative colitis. Surgery 2008; 144: 540 - 5.

62. Randall J, Singh B, Warren BF, et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010; 97: 404 - 9.

63. Yang Z, Wu Q, Wu K, et al. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 2010; 31: 486 - 92.

64. Kappelman M, Horvath-Puho E, Sandler RS, et al. The association between IBD and venous thromboembolism in Danish children and adults: A population-based case-control study. Gastroenterology 2010; 138: S-105 - 6

65. Aloi M, Cucchiara S. Extradigestive manifestations of IBD in pediatrics. Eur Rev Med Pharmacol Sci 2009; 13 (suppl 1): 23 - 32.

66. Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 63 - 8.

67. Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr 2010; 51: 140 - 5.

68. Hyams JS. Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 1994; 19: 7 - 21.

69. Hyams JS. Crohn's disease in children. Pediatr Clin North Am 1996; 43: 255 - 77.

70. Winesett M. Inflammatory bowel disease in children and adolescents. Pediatr Ann 1997; 26: 227 - 34.

71. Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am 2003; 32: 967 - 95.

72. Charatcharoenwitthaya P, Lindor KD. Primary sclerosing cholangitis: diagnosis and management. Curr Gastroenterol Rep 2006; 8: 75 - 82.

73. Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404 - 8.

74. Fevery J, Henckaerts L, Van Oirbeek R, et al. Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study. Liver Int 2012; 32: 214 - 22.

75. Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. Semin Liver Dis 2006; 26: 52 - 61.

76. Greenley RN, Stephens M, Doughty A, et al. Barriers to adherence among adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 36 - 41.

77. Hommel KA, Denson LA, Baldassano RN. Oral medication adherence and disease severity in pediatric inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011; 23: 250 - 4.

78. Hommel KA, Baldassano RN. Barriers to treatment adherence in pediatric inflammatory bowel disease. J Pediatr Psychol 2010; 35: 1005 - 10.

79. Reed-Knight B, Lewis JD, Blount RL. Association of disease, adolescent, and family factors with medication adherence in pediatric inflammatory bowel disease. J Pediatr Psychol 2011; 36: 308 - 17.

80. OCEBM Levels of Evidence Working Group. "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/ocebm-levels-of-evidence (http://www.cebm.net/ocebm-levels-of-evidence)

81. Turner D, Otley AR, Mack D, et al. Development and evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): a prospective multicenter study. Gastroenterology 2007; 133: 423 - 32. (http://www.cebm.net/ocebm-levels-of-evidence)